Research Reports

Prepared Highlights

Q1 2026 net sales of $27.6 million, up 57% year-over-year, driven by new patient starts and recurring revenue from the growing pharmacy installed base (CEO, CFO).
Gross margin of 59.5%, expanding 864 bps year-over-year and 52 bps sequentially; pharmacy installed base crossed the 3x threshold vs. new pharmacy starts, becoming accretive to margin (CFO).
New patient starts declined more than 10% but less than 20% sequentially from Q4 2025, in line with seasonal expectations (CFO).
Pharmacy channel mix: high 30s percentage of new patient starts (vs. low 30s in Q4 2025, low 20s in Q1 2025); no expected Q1-to-Q2 uptick due to plan change timing (CFO).
Approximately 70% of new patient starts came from people with diabetes previously using multiple daily injections (CFO).
Total operating expenses of $40.7 million, up 47% year-over-year; driven by sales force expansion, R&D for Mint and bihormonal, and G&A scaling (CFO).
Cash, equivalents, and investments of ~$240 million as of March 31, 2026 (CFO).
Official guidance (FY 2026, raised):
- Total revenue: $131M–$136M (prior: $130M–$135M)
- Pharmacy mix of new patient starts: 37%–39% (prior: 36%–38%)
- Gross margin: 57.5%–59.5% (prior: 55.5%–57.5%)
Pipeline: Mint patch pump on track for unconstrained commercial launch by end of 2027; bihormonal Phase IIa feasibility trial initiated in Q1 (CEO).
Mgmt quotes:
- "Our pharmacy strategy continues to deliver strong financial results for the business, driven by the advantaged recurring revenue model." (CFO)
- "We crossed that threshold in Q1, and we expect further gross margin expansion as our pharmacy installed base continues to grow." (CFO)
- "We believe that the existing body of evidence of bihormonal fully closed-loop algorithms shows the potential for the majority of people with diabetes to achieve the ADA's glycemic goals." (CEO)
- "We are building a business that we believe is uniquely positioned to succeed over the short, medium and long term." (CEO)
- "Our teams continue to execute relentlessly to deliver life-changing solutions to the diabetes community today and over the long term." (CEO)

Prepared Metrics

Metric	Value	Speaker/Context
Net Sales (Q1 2026)	$27.6M	CFO – 57% YoY growth
Gross Margin (Q1 2026)	59.5%	CFO – +864 bps YoY, +52 bps QoQ
Operating Expenses (Q1 2026)	$40.7M	CFO – 47% YoY increase
Cash & Investments (Mar 31, 2026)	~$240M	CFO – sufficiently capitalized
FY 2026 Revenue Guidance	$131M–$136M	CFO – raised from $130M–$135M
FY 2026 Pharmacy Mix Guidance	37%–39%	CFO – raised from 36%–38%
FY 2026 Gross Margin Guidance	57.5%–59.5%	CFO – raised from 55.5%–57.5%
New Patient Starts from MDI (Q1)	~70%	CFO – prior insulin pump users not specified
Type 2 New Patient Starts (Q1, off-label)	25%–30%	CEO – estimated

Q&A Batch (1-5 of 11)

Q1 — Michael Kratky

Topic: Pharmacy channel guidance and sales force expansion
Key points:
- Updated guidance for new starts through pharmacy channel is 37%–39%; biggest step-ups in pharmacy coverage occur in January and July.
- Pharmacy reimbursement is B2B with long sales cycles, not perfectly predictable.
- Competitors moving tubed pumps to pharmacy channel makes payers/PBMs more inclined to move insulin pumps to pharmacy reimbursement; no competitive pressure dampening guidance.
- Sales force expansion mostly in first half of year; most occurred in Q1, some in Q2, not in the “ninth inning.”
Mgmt stance: Bullish — sees competitor moves as positive for channel growth, no competitive headwinds.

Q2 — David Roman

Topic: ADA guideline changes, GLP-1 impact, and OpEx investment
Key points:
- ADA guideline changes (December) not yet impacting daily prescribing patterns; changes were subtle and take time to filter.
- GLP-1s (including orals) not a huge impact on type 1 or insulin-dependent type 2; oral evolution not expected to change that.
- Sales & marketing spend will grow into Q2 due to field sales expansion; Q1 2026 sales & marketing was 75% of revenue.
- Customer acquisition cost needs to decline; will improve via pharmacy installed base (high gross margin recurring revenue) and brand building for Mint product.
Mgmt stance: Neutral on GLP-1 impact; bullish on long-term OpEx efficiency and path to profitability.

Q3 — Frank Takkinen

Topic: Gross margin and cash burn
Key points:
- Q1 gross margin had onetime tailwinds (small but notable); not quantified.
- Guidance embeds openness to unpredictable onetime charges in cost of sales; Q1 performance not necessarily indicative of run rate.
- Pharmacy revenue model has higher gross margin than DME model in Q1, in early state.
- Q1 cash burn ~$25M, higher than adjusted EBITDA ~~$17M; difference due to cash bonus payments (~~$4M from working capital changes in inventory, AR, AP).
- Cash burn for rest of year expected to approximate adjusted EBITDA.
Mgmt stance: Bullish on long-term gross margin upside; neutral on short-term predictability.

Q4 — Jonathan Block

Topic: Revenue cadence and gross margin trajectory
Key points:
- First half of 2026 revenue weighting higher than first half of 2025; no quarterly revenue guidance given.
- Q1 gross margin had onetime favorability; sequential gross margin uptick still expected off normalized Q1 run rate.
- Analyst suggested ~200 bps tailwind; mgmt responded “bingo” without confirming exact number.
Mgmt stance: Neutral on quarterly guidance specifics; bullish on sequential gross margin improvement.

Q5 — Felipe Lamar

Topic: Pharmacy channel dynamics and long-term economics
Key points:
- More competitors entering durable pump pharmacy channel normalizes it, making it a “snowball” effect; more success brings more payer adoption.
- Insulin pumps are non-commoditized; scripts are product-specific (e.g., iLet) and cannot be switched without new script, limiting downward price pressure.
- Differentiated algorithms and clinical trial requirements prevent commoditization; iLet seen as one of the most differentiated products.
Mgmt stance: Bullish — multiple players positive for industry; channel economics expected to hold due to non-commoditized nature.

Q&A Batch (6-10 of 11)

Q6 — Jeffrey Johnson

Topic: Rebate strategy vs. co-pay buy-down for pharmacy channel tier positioning
Key points:
- Market non-commoditization limits payer downward price pressure; pricing durability expected for foreseeable future.
- Tier 2 vs. Tier 3 difference is only rebate required and user co-pay; Beta Bionics controls co-pay at $25 or less per month via assistance programs.
- Decision between tiers is a simple math problem balancing rebate cost vs. co-pay reduction; company will always pick the more advantaged tier.
Mgmt stance: Neutral – frames tier choice as a straightforward cost-benefit calculation with patient co-pay fixed, no directional preference stated.

Q7 — Matthew O'Brien

Topic: Type 2 growth contribution, type 1 growth trajectory, and R&D spending on Mint vs. bihormonal
Key points:
- 25%–30% of new users have type 2 diabetes; type 2 is a larger growth contributor than type 1 in Q1, but type 1 growth is not shrinking.
- Lack of type 2 indication hinders growth; company cannot promote product for type 2, but doctors prescribe off-label; indication is desired for medium/long term.
- R&D spike in Q1 vs. Q4 is not split by project; both bihormonal and Mint will see spending increases; Mint timeline reiterated as unconstrained launch by end of 2027, with no slippage.
Mgmt stance: Neutral on type 2 (acknowledges off-label growth but hindered by no indication); bullish on Mint timeline (consistent reiteration, no slippage).

Q8 — Jeffrey Cohen

Topic: Cost of materials drivers and bihormonal data/publication plans
Key points:
- Lower cost per unit in Q1 was primarily driven by volume/scale, not deflation.
- No plans to publish bihormonal IIa/IIb trial results; company will only announce completion, not upcoming milestones.
- 2026 should bring meaningful updates, but specifics not disclosed; past formative studies (published in the 2010s) show strong results.
Mgmt stance: Neutral on cost (scale-driven, not structural); cautious on bihormonal disclosure (no benefit seen in publishing trial data).

Q9 — Mathew Blackman

Topic: New patient add disclosure range and sales force expansion strategy
Key points:
- New patient adds disclosed as >10% but <20% Q-over-Q decline; management will not narrow the range further.
- Sales force expansion involves adding 20 territories; no true white space (rep covers everywhere), but many areas have no rep visits; expansion includes both under-covered areas and deeper coverage in existing territories.
- Hiring governed by finding good people, not just filling MSAs.
Mgmt stance: Neutral on disclosure (declines to comment beyond prepared remarks); neutral on expansion (describes as both filling gaps and deepening coverage, no specific execution risk flagged).

Q10 — Unknown Analyst (Grace)

Topic: 2026 revenue guidance conservatism and new patient start seasonality
Key points:
- 2026 revenue guidance implies ~$33M year-over-year dollar growth vs. $35M in 2025.
- Upside drivers: iLet confidence from endocrinologists, same-store sales traction, and new sales territories (most do not prescribe iLet today).
- Q1 is the weakest quarter seasonally; Q2 expected to see the largest sequential step change in new patient starts and revenue.
Mgmt stance: Neutral on guidance (sets with confidence but identifies upside levers); neutral on seasonality (reiterates Q1 weakness and Q2 uptick, no specific numbers).

Q&A Batch (11-11 of 11)

Q11 — Ryan Schiller

Topic: 竞争环境变化及公司定位
Key points:
- 竞争对手IPO对市场动态无实际影响；另一竞品全国发布的产品与市场现有产品相似，与BBNX产品差异显著，目标用户群不同。
- 竞争加剧会在边际上稀释所有参与者，但对BBNX影响有限；近期没有重大产品发布改变市场格局。
- BBNX目前聚焦于管路泵细分市场（较小份额），在新患者启动中持续获得有意义的份额，尤其在考虑销售团队规模较小的背景下。
Mgmt stance: 中性偏乐观——管理层对当前市场份额增长和产品差异化有信心，但承认需长期推进销售团队扩张和市场教育，以实现全国覆盖（Mint计划）。